Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Other financing activities (2016 - 2024)

Historic Other financing activities for Ani Pharmaceuticals (ANIP) over the last 11 years, with Q4 2024 value amounting to $2.0 million.

  • Ani Pharmaceuticals' Other financing activities changed N/A to $2.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.8 million, marking a year-over-year increase of 4435000.0%. This contributed to the annual value of $17.4 million for FY2024, which is N/A changed from last year.
  • Per Ani Pharmaceuticals' latest filing, its Other financing activities stood at $2.0 million for Q4 2024.
  • Over the past 5 years, Ani Pharmaceuticals' Other financing activities peaked at $13.6 million during Q4 2021, and registered a low of -$690000.0 during Q4 2022.
  • Moreover, its 4-year median value for Other financing activities was $203000.0 (2022), whereas its average is $1.5 million.
  • Over the last 5 years, Ani Pharmaceuticals' Other financing activities had its largest YoY gain of 4840000.0% in 2022, and its largest YoY loss of 10506.16% in 2022.
  • Over the past 4 years, Ani Pharmaceuticals' Other financing activities (Quarter) stood at $169000.0 in 2020, then surged by 7966.27% to $13.6 million in 2021, then crashed by 105.06% to -$690000.0 in 2022, then surged by 386.52% to $2.0 million in 2024.
  • Its Other financing activities was $2.0 million in Q4 2024, compared to -$690000.0 in Q4 2022 and $483000.0 in Q3 2022.